Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q2- Text added to 2016 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
Ablynx, Amgen, basket, biosimilar, bortezomib, Code, commenced, failed, glecaprevir, insignificant, intervening, MZL, naive, Nanobody, NDA, neuroendocrine, opted, Orange, pathway, protease, proteasome, provision, receipt, receptor, restitution, sensitive, Superior, unsuitable, VENCLEXTO, vobarilizumab, XR
Removed:
accrued, allocable, attributable, basic, British, calculation, comprised, Deferral, denominator, difficult, distributed, evolving, immaterial, inherently, meaningful, numerator, plan, Poor, pound, preparation, primary, qualify, refer, significantly, subjective, superseded, supported, uncertain, validated, variability, vary
Valuein 2016 Q2 filing- Value in 2016 Q3 filing
Original filings
Filing view